NasdaqCM - Nasdaq Real Time Price USD

RenovoRx, Inc. (RNXT)

0.8110

+0.0200

+(2.50%)

As of 9:44:33 AM EDT. Market Open.

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

MOUNTAIN VIEW, Calif., April 04, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the LD Micro Invitational XV: New York 2025 conference taking place at the Westin Grand Central Hotel, New York, NY on April 10, 2025.

Business Wire 7 days ago

RNXT
+2.50%
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

MOUNTAIN VIEW, Calif., April 01, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced its financial results and business updates for the fourth quarter and full year ended December 31, 2024.

Business Wire 10 days ago

RNXT
+2.50%
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

MOUNTAIN VIEW, Calif., March 28, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, announced today that a new human pharmacokinetic (PK) data abstract was presented at the Society of Surgical Oncology (SSO) 2025 Annual Meeting on March 27 – 29, 2025 in Tampa, FL: ePoster P379.

Business Wire 14 days ago

RNXT
+2.50%
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

MOUNTAIN VIEW, Calif., March 26, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, is proud to announce that a publication supporting the Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for targeted locoregional drug delivery will be recognized in the Journal of Vascular and Interventional Radiology (JV

Business Wire 16 days ago

RNXT
+2.50%
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

MOUNTAIN VIEW, Calif., March 20, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that it will host a fireside chat with Shaun Bagai, Chief Executive Officer, on Thursday, April 3, 2025, at 12:00 p.m. ET.

Business Wire 22 days ago

RNXT
+2.50%
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

MOUNTAIN VIEW, Calif., March 19, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, is proud to announce a presentation of a new pre-clinical clinical data abstract at the upcoming Society of Surgical Oncology (SSO) 2025 Annual Meeting.

Business Wire 23 days ago

RNXT
+2.50%
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

MOUNTAIN VIEW, Calif., February 26, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced continuing momentum with the Company’s RenovoCath commercial strategy, with new purchase orders received from several esteemed, high volume National Cancer Institute-designated centers.

Business Wire last month

RNXT
+2.50%
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

MOUNTAIN VIEW, Calif., February 13, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, highlighted its recent abstract presentation at the 2025 Society of Interventional Oncology Annual Conference ("SIO 2025") in Las Vegas, Nevada. The abstract published promising pre-clinical data from the use of RenovoRx’s patented Trans-Arterial Micro-Perfusio

Business Wire last month

RNXT
+2.50%
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

MOUNTAIN VIEW, Calif., February 11, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, an innovative, FDA-cleared delivery platform, today announced the closing of its previously announced $12.1 million firm commitment underwritten public offering of common stock led by multiple fundamental healthcare institutional investors.

Business Wire last month

RNXT
+2.50%
RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement

The company plans to use the proceeds for ongoing clinical trials and commercialization efforts.

GuruFocus.com 2 months ago

RNXT
+2.50%
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

MOUNTAIN VIEW, Calif., February 07, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced the pricing of a firm commitment, underwritten public offering of 11,523,810 shares of its common stock at a price to the public of $1.05 per share. All shares in the offering are being sold by RenovoRx.

Business Wire 2 months ago

RNXT
+2.50%
RenovoRx Announces Proposed Public Offering

MOUNTAIN VIEW, Calif., February 06, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of common stock. All of the securities to be sold in the proposed offering will be offered by RenovoRx. The propo

Business Wire 2 months ago

RNXT
+2.50%
ASCO GI: RenovoRX’s TAMP system reduces side effects in pancreatic cancer

The data revealed that the use of the Trans-Arterial Micro-Perfusion (TAMP) device resulted in greater drug potency and fewer side effects.

Clinical Trials Arena 2 months ago

RNXT
+2.50%
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

MOUNTAIN VIEW, Calif., January 27, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced an abstract presentation highlighting promising pharmacokinetic (known as PK) data from the use of RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform in treating locally advanced pancreatic cancer (LAPC).

Business Wire 2 months ago

RNXT
+2.50%
Analysts Expect Breakeven For RenovoRx, Inc. (NASDAQ:RNXT) Before Long

RenovoRx, Inc. ( NASDAQ:RNXT ) is possibly approaching a major achievement in its business, so we would like to shine...

Simply Wall St. 2 months ago

RNXT
+2.50%
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

MOUNTAIN VIEW, Calif., January 08, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced three abstracts were accepted to be presented at several upcoming industry conferences including ASCO Gastrointestinal Cancers Symposium (ASCO GI) 2025, Society of Interventional Oncology (SIO) 2025 and Society of Surgical Oncology (SSO) 20

Business Wire 3 months ago

RNXT
+2.50%
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

MOUNTAIN VIEW, Calif., December 30, 2024--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery system, today highlighted its strong intellectual property (IP) position as it moves forward with commercial plans and clinical trial advancement in 2025, utilizing its novel Trans-Arterial Micro-Perfusion (TAMP) therapy platform.

Business Wire 3 months ago

RNXT
+2.50%
RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer

TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer Dr. Meredith Pelster, Associate Director for GI Research Across Sarah Cannon Research Institute (SCRI), Appointed Principal Investigator for TIGeR-PaC Study LOS ALTOS, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing

GlobeNewswire 3 months ago

RNXT
+2.50%
RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET

Shaun Bagai to discuss RenovoRx’s 2024 achievements and 2025 outlook, including important milestones for commercialization of RenovoCath and Phase III TIGeR-PaC trialLOS ALTOS, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced that it will host an investor fireside chat on Tuesday, Decemb

GlobeNewswire 3 months ago

RNXT
+2.50%
RenovoRx begins commercialisation of RenovoCath device

More than ten medical institutions have initiated purchase order processes for the RenovoCath device.

Medical Device Network 4 months ago

RNXT
+2.50%

Performance Overview

Return	RNXT	S&P 500 (^GSPC)
YTD	-37.13%	-9.98%
1-Year	-37.13%	+1.84%
3-Year	-70.93%	+20.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

RenovoRx, Inc. (RNXT)

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Proposed Public Offering

ASCO GI: RenovoRX’s TAMP system reduces side effects in pancreatic cancer

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Analysts Expect Breakeven For RenovoRx, Inc. (NASDAQ:RNXT) Before Long

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer

RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET

RenovoRx begins commercialisation of RenovoCath device

Performance Overview